aTYR PHARMA INC (ATYR) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $98.00K; Additional Paid in CapitalUSD $676.02M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-68.00K; Retained Earnings (Accumulated Deficit)USD $-627.26M.
- 2026-03-31: Common Stock, Value, IssuedUSD $98.00K; Additional Paid in CapitalUSD $674.86M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-70.00K; Retained Earnings (Accumulated Deficit)USD $-616.96M.
- 2025-12-31: Common Stock, Value, IssuedUSD $98.00K; Additional Paid in CapitalUSD $673.55M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-8.00K; Retained Earnings (Accumulated Deficit)USD $-606.16M.
- 2025-09-30: Common Stock, Value, IssuedUSD $98.00K; Additional Paid in CapitalUSD $672.34M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.00K; Retained Earnings (Accumulated Deficit)USD $-592.20M.
aTYR PHARMA INC Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Preferred Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock USD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $98.00K | $676.02M | $-68.00K | $-627.26M | $48.79M | $48.59M | 3 month · $1.15M | (m) | (m) | (m) | (m) |
| 2026-03-31 | $98.00K | $674.86M | $-70.00K | $-616.96M | $57.93M | $57.74M | 3 month · $1.31M | (m) | (m) | (m) | (m) |
| 2025-12-31 | $98.00K | $673.55M | $-8.00K | $-606.16M | $67.48M | $67.29M | 12 month · $5.00M | (m) | (m) | (m) | (m) |
| 2025-09-30 | $98.00K | $672.34M | $-1.00K | $-592.20M | $80.23M | $80.04M | 3 month · $1.31M | (m) | (m) | (m) | (m) |
| 2025-06-30 | $93.00K | $641.28M | $-75.00K | $-566.46M | $74.84M | $74.66M | 3 month · $1.30M | (m) | (m) | (m) | (m) |
| 2025-03-31 | $89.00K | $621.95M | $-66.00K | $-546.93M | $75.05M | $74.86M | 3 month · $1.18M | (m) | (m) | (m) | (m) |
| 2024-12-31 | $84.00K | $602.02M | $-40.00K | $-532.05M | $70.02M | $69.83M | 12 month · $2.99M | (m) | (m) | (m) | (m) |
| 2024-09-30 | $76.00K | $582.29M | $36.00K | $-517.08M | $65.33M | $65.14M | 3 month · $752.00K | (m) | (m) | (m) | (m) |
| 2024-06-30 | $76.00K | $581.52M | $-168.00K | $-499.82M | $81.61M | $81.42M | 3 month · $727.00K | (m) | (m) | (m) | (m) |
| 2024-03-31 | $68.00K | $568.07M | $-158.00K | $-483.51M | $84.47M | $84.28M | 3 month · $740.00K | (m) | (m) | (m) | (m) |
| 2023-12-31 | $63.00K | $558.69M | $-74.00K | $-468.02M | $90.66M | $90.47M | 12 month · $2.60M | (m) | (m) | (m) | (m) |
| 2023-09-30 | $59.00K | $551.89M | $-294.00K | $-453.26M | $98.39M | $98.20M | 3 month · $664.00K | (m) | (m) | (m) | (m) |
| 2023-06-30 | $57.00K | $548.44M | $-333.00K | $-441.92M | $106.24M | $106.05M | 3 month · $658.00K | (m) | (m) | (m) | (m) |
| 2023-03-31 | $53.00K | $539.66M | $-248.00K | $-429.58M | $109.88M | $109.70M | 3 month · $619.00K | (m) | (m) | (m) | (m) |
| 2022-12-31 | $29.00K | $489.50M | $-433.00K | $-417.63M | $71.46M | $71.28M | 12 month · $2.15M | (m) | (m) | (m) | (m) |
| 2022-09-30 | $29.00K | $487.94M | $-669.00K | $-410.11M | $77.18M | $77.01M | 3 month · $615.00K | (m) | (m) | (m) | (m) |
| 2022-06-30 | $28.00K | $484.29M | $-810.00K | $-396.87M | $86.64M | $86.46M | 3 month · $517.00K | (m) | (m) | (m) | (m) |
| 2022-03-31 | $28.00K | $483.73M | $-759.00K | $-384.45M | $98.55M | $98.37M | 3 month · $417.00K | (m) | (m) | (m) | (m) |
| 2021-12-31 | $28.00K | $481.83M | $-263.00K | $-372.30M | $109.30M | $109.13M | 12 month · $1.61M | (m) | (m) | (m) | (m) |
| 2021-09-30 | $28.00K | $481.39M | $-69.00K | $-363.74M | $117.61M | $117.44M | 3 month · $442.00K | (m) | (m) | (m) | (m) |
| 2021-06-30 | $16.00K | $397.09M | $-61.00K | $-356.07M | $40.98M | $40.80M | 3 month · $398.00K | (m) | (m) | (m) | (m) |
| 2021-03-31 | $16.00K | $395.42M | $-57.00K | $-345.68M | $49.70M | $49.53M | 3 month · $360.00K | (m) | (m) | (m) | (m) |
| 2020-12-31 | $11.00K | $370.21M | $-43.00K | $-338.53M | $31.65M | $31.48M | 12 month · $1.47M | (m) | (m) | (m) | (m) |
| 2020-09-30 | $10.00K | $365.79M | $-42.00K | $-333.60M | $32.16M | $32.00M | 3 month · $324.00K | (m) | (m) | (m) | (m) |
| 2020-06-30 | $9.00K | $363.13M | $-44.00K | $-327.00M | $36.10M | $35.94M | 3 month · $378.00K | (m) | (m) | (m) | (m) |
| 2020-03-31 | $9.00K | $362.72M | $-53.00K | $-320.55M | $42.13M | $41.97M | 3 month · $423.00K | (m) | (m) | (m) | (m) |
| 2019-12-31 | $4.00K | $343.52M | $-40.00K | $-322.30M | $21.19M | $21.03M | 12 month · $1.78M | $2.00K | (m) | (m) | (m) |
| 2019-09-30 | $50.00K | $343.05M | $-33.00K | $-316.33M | $26.74M | (m) | 3 month · $278.00K | $2.00K | (m) | (m) | (m) |
| 2019-06-30 | $49.00K | $340.89M | $-32.00K | $-310.69M | $30.23M | (m) | 3 month · $509.00K | $2.00K | (m) | (m) | (m) |
| 2019-03-31 | $37.00K | $334.32M | $-40.00K | $-304.84M | $29.48M | (m) | 3 month · $571.00K | $2.00K | (m) | (m) | (m) |
| 2018-12-31 | $2.00K | $332.41M | $-60.00K | $-298.70M | $33.65M | $33.65M | 12 month · $3.43M | $2.00K | (m) | (m) | (m) |
| 2018-09-30 | $30.00K | $331.39M | $-57.00K | $-292.38M | $38.99M | (m) | 3 month · $690.00K | $2.00K | (m) | (m) | (m) |
| 2018-06-30 | $30.00K | $330.69M | $-85.00K | $-285.26M | $45.38M | (m) | 3 month · $1.21M | $2.00K | (m) | (m) | (m) |
| 2018-03-31 | $30.00K | $329.45M | $-136.00K | $-274.85M | $54.50M | (m) | 3 month · $928.00K | $2.00K | (m) | (m) | (m) |
| 2017-12-31 | $30.00K | $328.52M | $-120.00K | $-264.19M | $64.25M | (m) | 12 month · $6.78M | $2.00K | (m) | 12 month · $263.00K | (m) |
| 2017-09-30 | $30.00K | $325.03M | $-63.00K | $-252.71M | $72.29M | (m) | (m) | $2.00K | (m) | (m) | (m) |
| 2017-06-30 | $24.00K | (m) | $-57.00K | $-241.52M | $40.03M | (m) | (m) | (m) | $281.59M | (m) | (m) |
| 2017-03-31 | $24.00K | (m) | $-68.00K | $-229.38M | $50.71M | (m) | (m) | (m) | $280.13M | (m) | (m) |
| 2016-12-31 | $24.00K | $278.83M | $-76.00K | $-215.98M | $62.80M | (m) | 12 month · $5.03M | (m) | $278.83M | 12 month · $217.00K | (m) |
| 2016-09-30 | $24.00K | (m) | $7.00K | $-203.41M | $73.99M | (m) | (m) | (m) | $277.37M | (m) | (m) |
| 2016-06-30 | $24.00K | (m) | $19.00K | $-189.59M | $86.57M | (m) | (m) | (m) | $276.12M | (m) | (m) |
| 2016-03-31 | $24.00K | (m) | $-19.00K | $-174.21M | $100.43M | (m) | (m) | (m) | $274.64M | (m) | (m) |
| 2015-12-31 | $24.00K | (m) | $-171.00K | $-158.12M | $115.05M | (m) | 12 month · $4.86M | (m) | $273.32M | (m) | 12 month · $15.00K |
| 2015-09-30 | $24.00K | (m) | $-68.00K | $-141.63M | $129.16M | (m) | (m) | (m) | $270.83M | (m) | (m) |
| 2015-06-30 | $24.00K | (m) | $-106.00K | $-130.30M | $139.34M | (m) | (m) | (m) | $269.73M | (m) | (m) |
| 2015-03-31 | $1.00K | (m) | (m) | $-119.22M | $-98.01M | (m) | (m) | (m) | $21.21M | (m) | (m) |
| 2014-12-31 | $1.00K | (m) | (m) | $-110.15M | $-91.01M | (m) | 12 month · $1.79M | (m) | $19.21M | (m) | 12 month · $416.00K |
| 2013-12-31 | (m) | (m) | (m) | (m) | $-66.08M | (m) | 12 month · $155.00K | (m) | (m) | (m) | 12 month · $1.64M |
| 2012-12-31 | (m) | (m) | (m) | (m) | $-64.55M | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |